PubMed · 5022740
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
A C Maddocks, G Raine. 1972-04-22. Contaminated drip fluids.. https://doi.org/10.1136/bmj.2.5807.231-a
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
Explore the source record for details and available documents.
The separation and detection of acidic and neutral impurities in illicit heroin using capillary electrophoresis (CE) is described. Separations were achieved using charged cyclodextrin modified micellar electrokinetic capillary chromatography. The use of the anionic beta-cyclodextrin sulfobutyl ether 1V in combination with sodium dodecyl sulfate significantly increased resolution. Improved selectivity and/or sensitivity in detection was obtained using photodiode array ultraviolet and laser-induced fluorescence detection. The phenanthrene-like heroin impurities exhibit high native fluorescence under krypton-fluoride laser excitation (248 nm). The limit of detection by laser-induced fluorescence detection for one of these solutes (acetylthebaol) is 1.8 ng/ml, 500 times more sensitive than UV. This methodology is applicable to analysis of both crude and refined heroin.
The efficiency and consistency of a biopharmaceutical purification process determines drug quality, including which specific types and concentrations of residual host cell or process contaminants may remain. Commercial reagents and generic analytical methods are available for quantitating most of these contaminants. However, no generic assay is available for quantitation of the specific contaminant host cell proteins (HCPs) which are unique to a novel purification process. Because of this, proprietary reagents and assays must be developed for the quantitation of process-specific HCPs in each biopharmaceutical drug. The need to develop proprietary reagents which are both sensitive to, and specific for, potentially complex mixtures of unique contaminant proteins has defined what is acceptable methodology for development of quantitative HCP assays. Within the biopharmaceutical industry this need is most often satisfied by the development of multi-analyte HCP immunoassays based upon the null cell mock purification model. Confidence in the quantitative nature of a given HCP assay, and the validity of analytical measurement obtained by the assay, is dependent upon empirical demonstration of the unique stoichiometry of the HCP assay reagents. In conjunction with other analytical and validation methods, an HCP immunoassay may be thought of as a necessary quantitative tool for the optimization and validation of biopharmaceutical purification process efficiency and consistency, rather than as an end in itself.